In multicellular organisms, angiogenesis, the formation of new blood vessels from pre-
existing ones, is an essential process for growth and development. Different mechanisms …

Congenital vascular malformations (CVMs) are the result of an aberrant development during
embryogenesis. Although these lesions are present at birth, they are not always visible yet …

BACKGROUND Slow-flow vascular malformations frequently harbor activating mutations in
the PI3K/AKT/mTOR cascade. Phase II trials pinpointed sirolimus effectiveness as a drug …

Abstract The Kasabach-Merritt phenomenon (KMP) in kaposiform hemangioendothelioma
(KHE) is characterized by life-threatening thrombocytopenia and consumptive coagulopathy …

Abstract Treatment with sirolimus, an inhibitor of the mammalian target of rapamycin
pathway, has improved the prognosis of patients with kaposiform hemangioendothelioma …

Abstract (119/250 words) Vascular malformations, which arise from anomalies in
angiogenesis, encompass capillary, lymphatic, venous, arteriovenous and mixed …

Background: Sirolimus, a mammalian target of rapamycin inhibitor, has been widely used in
pediatric patients, but the safety of sirolimus in pediatric patients has not been well …

Background and objectives Initially developed as immunosuppressive agents, mammalian
target of rapamycin (mTOR) inhibitors are currently used widely in the management of …

Background Significant variation in management strategies for lymphatic malformations
(LMs) in children persists. The goal of this systematic review is to summarize outcomes for …

Objective This study is a systematic review and meta‐analysis of the efficacy and safety of
sirolimus in the management of pediatric cervicofacial lymphatic malformations (LMs). Data …